Search Results - "Schellekens, P.T.A"

Relationship Between Patterns of Engraftment in Peripheral Blood and Immune Reconstitution After Allogeneic Bone Marrow Transplantation for (Severe) Combined Immunodeficiency by van Leeuwen, J.E.M., van Tol, M.J.D., Joosten, A.M., Schellekens, P.T.A., van den Bergh, R. Langlois, Waaijer, J.L.M., Oudeman-Gruber, N.J., van der Weijden-Ragas, C.P.M., Roos, M.T.L., Gerritsen, E.J.A., van den Berg, H., Haraldsson, A., Khan, P. Meera, Vossen, J.M.

“…We report the outcome of allogeneic bone marrow transplantation (BMT) as treatment for severe combined immunodeficiency disease (SCID) in 31 patients grafted…”
Get full text

Colorectal cancer in patients with X-linked agammaglobulinaemia by van der Meer, J W, Weening, R S, Schellekens, P T, van Munster, I P, Nagengast, F M

“…Primary immunodeficiency disorders can predispose to certain malignancies but hitherto no such relation has been established for X-linked agammaglobulinaemia…”
Get more information

Whole-blood lymphocyte cultures by Bloemena, E, Roos, M T, Van Heijst, J L, Vossen, J M, Schellekens, P T

“…A simple and reproducible method is described for the measurement of proliferative responses of peripheral blood lymphocytes in whole blood upon stimulation…”
Get more information

Quantification of TCR/CD3 complex expression on human T-lymphocytes after in vivo treatment with murine IgA monocional antibody to human CD3 by Meijer, R.T., Yong, S.L., ten Berge, R.J.M., Schellekens, P.T.A.

Get full text

No long-term benefit of low-dose OKT3 induction therapy in non to moderately immunized renal allograft recipients by Bemelman, F.J, Yong, S, Parlevliet, K.J, Surachno, S, Schellekens, P.T.A, ten Berge, R.J.M

Get full text

OKT3 versus methylprednisolone for primary treatment of rejection: a retrospective evaluation by Meijer, R.T, Keur, I, Surachno, S, ten Berge, I.J.M, Schellekens, P.T.A

Get full text

Treatment of acute kidney allograft rejection with the nonmitogenic CD3 mAb CLB T3/4.A (IgA-CD3): absence of a correlation of clinical responsiveness with inhibition of lymphocyte reactivity in vitro by Meijer, R.T, Yong, S.L, Surachno, S, ten Berge, I.J.M, Schellekens, P.T.A

Get full text

Immunological reconstitution after triple combination therapy in HIV-1 infection by Pakker, N.G., Notermans, D.W., Miedema, F., de Boer, R., Roos, M.T.L., Koot, M., Goodwin, C., Leonard, J.M., Danner, S.A., Schellekens, P.T.A.

Get full text

Guidelines for the optimal use of muromonab CD3 in transplantation by ten Berge, I J, Parlevliet, K J, Raasveld, M H, Buysmann, S, Bemelman, F J, Schellekens, P T

“…Muromonab CD3 (OKT3), the murine anti-CD3 monoclonal antibody (mAb) of the IgG-2a class, directed against the CD3 molecule on the surface of human T cells, has…”
Get full text

Selective expansion of a peripheral blood CD8+ memory T cell subset expressing both granzyme B and l-selectin during primary viral infection in renal allograft recipients by ten Berge, I.J.M, Wever, P.C, Rentenaar, R.J, Spaeny, L.H.A, Surachno, J, Wertheim, P.M.E, Schellekens, P.T.A, Hack, C.E

Get full text

Concomitant detection by flow cytometry of the intragranular antigen granzyme B and the intranuclear antigen Ki-67 in peripheral blood mononuclear cells from healthy individuals and patients with acute CMV infection after renal transplantation by Rentenaar, R.J, Wever, P.C, van Diepen, F.N.J, Out, T.A, Schellekens, P.T.A, ten Berge, I.J.M

Get full text

Monoclonal antibodies in renal transplantation: a review by Parlevliet, K J, Schellekens, P T

“…OKT3 is the first anti-CD3 monoclonal antibody available for treatment in humans. Over the last few years it has proven to be a very powerful immunosuppressive…”
Get more information

Levamisole in Crohn's disease--a double-blind controlled trial by Wesdorp, E, Schellekens, P T, Weening, R S, Meuwissen, S G, Tytgat, G N

“…The efficacy of levamisole in patients with mildly active Crohn's disease was evaluated in a double-blind, placebo-controlled trial by means of clinical,…”
Get more information